// App-Quantinova.ai

: ILC2-driven innate immune checkpoint mechanism antagonizes NK cell anti-metastatic function in the lung.

Researchers

Presenter

  • Timotheus You Fu Halim

Principal Investigators

  • Shaun Png

  • Arianne Richard

  • Anastasia Tsyben

  • Gregory Hamm

  • Julie Stockis

  • Celine Garcia

  • Silvain Pinaud

  • Ashley Nichols

  • Xavier Romero-Ros

  • Jacqueline Shields

  • E. Suzanne Cohen

  • Andrew McKenzie

  • Richard Goodwin

  • Jing Su

  • Matthew Eldridge

  • Angela Riedel

  • Eva Serrao

  • Kevin Brindle

  • John Marioni

Medical Centers

  • Cambridge Inst. for Med. Res., Univ. of Cambridge, UK, United Kingdom

  • Cancer Res. UK - Cambridge Inst., Univ. of Cambridge, UK, United Kingdom

  • Biosci. Asthma, Res. and Early Develop., Resp. & Immunology, BioPharmaceuticals R&D, AstraZeneca, United Kingdom

  • MRC Lab. of Mol. Bio., United Kingdom

  • MRC Cancer Unit, Cambridge, United Kingdom

  • Cancer Res. UK - Cambridge Inst., Univ. of Cambridge, UK, United Kingdom

  • Imaging and Data Analytics, Clin. Pharmacology and Safety Sci., BioPharmaceuticals R&D, AstraZeneca, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Natural Killer cells

  • Microsatellite instability

Drug/Treatment

  • Interleukin

  • Interferon

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved